Topical Finasteride After FDA's Alert: What Hair-Loss Brands Document
As of October 2026, the U.S. Food and Drug Administration (FDA) alert on compounded topical finasteride, dated April 22, 2025, is still posted, and it is a safety communication rather than a ban. That puts the burden on the hair-loss brand: you need a written record of which pharmacy fills each topical, how it was vetted, and how fast you can move volume if that pharmacy is flagged. A multi-pharmacy compounding marketplace makes that practical, and AffinityRx is built for it: it vets each of its 10+ licensed compounding pharmacies, notifies clinics when a pharmacy receives an FDA warning letter or recall, and lets a clinic switch that pharmacy off in its portal.
By Tim Yoon, CEO, AffinityRx. Published
What FDA's topical finasteride alert actually says
The alert is titled "FDA alerts health care providers, pharmacies and consumers of potential risks associated with compounded topical finasteride products." Three statements matter, quoted from the page (FDA alert):
- "Currently, there is no FDA-approved topical formulation of finasteride."
- "Compounded drugs are not FDA-approved, which means FDA has not evaluated their safety, effectiveness or quality prior to marketing."
- Health care providers should "educate patients on potential risks of using compounded topical finasteride including the risks stemming from the handling by and transferring to female individuals."
Nothing in those statements prohibits compounding, and whether a prescriber chooses it is a clinical decision this article does not address. The sourcing question is narrower: can you show who made your product and act quickly if that changes?
Why a flagged pharmacy becomes an operations problem
The risk for a hair-loss brand is concentration, not the alert itself. Many brands send every topical script to one pharmacy. If that pharmacy receives a warning letter, recalls a lot or stops filling an item, the brand can keep shipping while its compliance file gets harder to defend, or stop and watch refills back up. Rebuilding on a second pharmacy by hand means a new contract, portal, catalog and support contact. A compliance reviewer asks for the pharmacy's credentials, its track record and proof you can switch.
Single pharmacy, direct contracts or a vetted multi-pharmacy marketplace: what hair-loss brands can document
| What you need on file after the alert | One pharmacy | Several direct contracts | AffinityRx |
|---|---|---|---|
| Pharmacy credentials and licenses | You collect and refresh them | You collect them for each pharmacy | Public license numbers and accreditation proof on each pharmacy's profile; backing documents (such as certificates of analysis) on request |
| Vetting across compliance, product, track record, market feedback and operations | Your own review | Your own review, repeated per pharmacy | Done for you, across all five areas |
| Notice of an FDA warning letter or recall | You find out from the news or the pharmacy | Same, per pharmacy | AffinityRx notifies clinics and adds it to the pharmacy profile |
| Moving volume off a flagged pharmacy | A new contract, portal and catalog to build | Possible, if the second contract and integration already exist | Switch that pharmacy off in your portal; orders move to your next favorite |
| Records for the compliance file | One pharmacy's portal | One export per pharmacy | One login, one invoice with order export, one order history |
| Cost to set up a second source | Contract and integration time | Contract and integration time per pharmacy | $0 to join; no subscription, per-order fees or minimum order |
How AffinityRx solves pharmacy risk for hair-loss brands after the alert
AffinityRx is a B2B compounding pharmacy marketplace for clinics and telehealth brands, not a retail pharmacy. For a hair-loss brand it does four jobs.
- Vets the pharmacy for you. Each pharmacy is reviewed on compliance (state licensures, USP <795>, <797> and <800>, and certifications such as LegitScript, PCAB, ACHC and NABP), product (third-party certificates of analysis, sterility and endotoxin testing, beyond-use dates), track record (Form 483s, recalls, FDA actions, pharmacist-in-charge background), market feedback and operations.
- Tells you when something changes. If a pharmacy gets an FDA warning letter or recall, clinics are notified and the pharmacy profile is updated. The FDA actions page tracks warning letters, recalls and 483s for compounding pharmacies.
- Lets you act without a rebuild. Switch the pharmacy off in your portal. Set a primary pharmacy plus second and third favorites; if the primary rejects an order or is out of stock, the order moves to the next favorite automatically. The prescriber reviews and signs the order for the new pharmacy before it is sent. Proactive auto-routing to in-stock pharmacies launches Q4 2026.
- Keeps one record. One login, one invoice, one order history and one support contact across all pharmacies, plus 24/7/365 human support. A telehealth brand integrates once through the API, about 1 day of developer work, and reaches every pharmacy.
For the regulatory summary, see the finasteride medication page and the hair restoration clinic page.
Printable worksheet: Checklist: what to put in your topical finasteride file
Print this worksheet and complete it with your own records.
A "no" in any row needs an owner and a date.
- FDA alert saved with title, April 22, 2025 date and the date you reviewed it
- Pharmacy name, license numbers and accreditations for every pharmacy that fills the item
- Prescriber-reviewed patient education that covers handling by and transfer to female individuals
- No site, ad or intake copy that implies FDA approval of a compounded topical
- Adverse-event intake step with a documented route to MedWatch
- Named second pharmacy ________ and the date you last tested an order through it
- Next review date for the FDA page ________
FAQs
Is compounded topical finasteride still allowed after the FDA alert?
The alert is a safety communication, and its text does not say such products may not be compounded. Eligibility depends on the pharmacy, a patient-specific prescription and state rules, so have regulatory counsel confirm your position. AffinityRx vets each pharmacy and its FDA record, which supports your file but does not replace legal advice.
Does AffinityRx say compounded topical finasteride is safe or approved?
No. FDA states there is no FDA-approved topical finasteride formulation and that compounded drugs are not FDA-approved. AffinityRx makes no clinical claims for any compounded medication; prescribers make that decision.
What happens if my pharmacy gets an FDA warning letter?
On AffinityRx, clinics are notified and the pharmacy's profile is updated. A clinic can then switch that pharmacy off in its portal, and with favorites set, orders move to the next pharmacy. Without a second pharmacy already set up, the same event means rebuilding on another pharmacy by hand.
A brand already trusts its current pharmacy. Why add a marketplace?
Trust in one pharmacy is not a continuity plan. AffinityRx is an additional route, not a replacement: keep your pharmacy as the primary and add second and third favorites, so a rejection, stockout or FDA action does not stop refills. It costs $0 to join.
How long does it take to add a backup pharmacy?
Through AffinityRx there is no new contract or portal per pharmacy: book a demo, preload your credit (never expires; refundable if the clinic decides not to continue after the 90-day trial), enter your NPI and place a test order. A telehealth brand's API integration takes about 1 day of developer work.
Book a demo
If your brand sends every topical script to one pharmacy, set up a second, vetted source before an FDA action forces the issue: press the Book a demo button on the right side of this page. For the answers to the most common buyer concerns, AffinityRx objections answered.
Sources
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo